Q5154 HCPCS code: Injection, omalizumab-igec (omlyclo), biosimilar, 5 mg
Q5154 is the HCPCS Level II code for injection, omalizumab-igec (omlyclo), biosimilar, 5 mg. Its Medicare coverage code is C (Carrier judgment): Coverage is decided by the Medicare contractor (MAC) case by case.
Code details
| Field | Value |
|---|---|
| Section | Q codes — Temporary codes |
| Coverage code | C — Carrier judgment |
| Pricing indicator | 51 — Drug or biological (priced per ASP/average sales price rules) |
| BETOS category | O1E — Other drugs |
| Added | 2025-10-01 |
| Last action effective | 2025-10-01 |
Medicare policy articles for this code
- A52448: Billing and Coding: Omalizumab and biosimilar, OMLYCLO® (omalizumab-igec) (Wellpoint Federal (MAC - Part A, MAC - Part B))
Covered diagnoses (17 ICD-10-CM codes)
The diagnoses most often listed as covered in the policy articles above:
| ICD-10-CM | Diagnosis | Articles listing it |
|---|---|---|
| J33.0 | Polyp of nasal cavity | 1 |
| J45.40 | Moderate persistent asthma, uncomplicated | 1 |
| J45.41 | Moderate persistent asthma with (acute) exacerbation | 1 |
| J45.42 | Moderate persistent asthma with status asthmaticus | 1 |
| J45.50 | Severe persistent asthma, uncomplicated | 1 |
| J45.51 | Severe persistent asthma with (acute) exacerbation | 1 |
| J45.52 | Severe persistent asthma with status asthmaticus | 1 |
| L50.1 | Idiopathic urticaria | 1 |
| L50.6 | Contact urticaria | 1 |
| L50.8 | Other urticaria | 1 |
Showing 10 of 17. The full list, non-covered diagnoses and CSV export are in Caduvo.
What changed for Q5154
- October 2025: Code appears in this HCPCS release
- 2025-10-01: Q5154 added to HCPCS Level II
- Next scheduled CMS quarterly update (HCPCS and DMEPOS fee schedule): 2027-01-01
Frequently asked questions
What is HCPCS code Q5154?
Q5154 is the HCPCS Level II code for injection, omalizumab-igec (omlyclo), biosimilar, 5 mg. Short descriptor: "Inj, omlyclo, 5 mg".
Does Medicare cover Q5154?
Coverage code C — Carrier judgment. Coverage is decided by the Medicare contractor (MAC) case by case.
Which diagnoses support coverage for Q5154?
Medicare policy articles that cite Q5154 list 17 covered ICD-10-CM diagnosis codes across 1 article. The most cited include J33.0 (Polyp of nasal cavity), J45.40 (Moderate persistent asthma, uncomplicated), J45.41 (Moderate persistent asthma with (acute) exacerbation). A listed diagnosis is necessary but not sufficient; the policy's other criteria still apply.
Related Q51 codes
- Q5100 — Injection, ustekinumab-kfce (yesintek), biosimilar, 1 mg
- Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
- Q5102 — Injection, infliximab, biosimilar, 10 mg
- Q5103 — Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg
- Q5104 — Injection, infliximab-abda, biosimilar, (renflexis), 10 mg
- Q5105 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units
- Q5106 — Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units
- Q5107 — Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg
- Q5108 — Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
- Q5109 — Injection, infliximab-qbtx, biosimilar, (ixifi), 10 mg
- Q5110 — Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
- Q5111 — Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg
Building a device that would bill under a code like this? Caduvo matches a device description to HCPCS/CPT codes, Medicare coverage and payment, and the FDA pathway in one report.
Next steps
- Run a reimbursement report for a device billed under Q5154
- Watch Q5154 for fee, coverage and descriptor changes
- Build a full Medicare revenue model for Q5154
Compiled by Caduvo from public CMS (Medicare) records, HCPCS release October 2026. Fees are Medicare allowables, not commercial rates. Not reviewed or endorsed by CMS. Not billing or legal advice. Report an error. Data and corrections policy.